Abstract
Myelosuppression is the major side effect of most anticancer cytotoxic drugs. Low concentrations of cytosine arabinoside (Ara-C), 6-thioguanine (6-Th), actinomycin-D (Act-D) and aclacinomycin A (ACM) have been reported to induce differentiation of leukaemic cell lines. With the proposed clinical trials of low-dosage of these four drugs, their effect on the differentiation of normal human myeloid progenitor marrow cells was studied. The four cytotoxic anticancer drugs at low concentrations stimulated normal human myeloid differentiation. Low dosage Ara-C has been used with great success in several clinical trials. The results suggest a similar therapeutic role for the other three anticancer drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lohmann H, Schreml W:Cytotoxic Drugs and the Granulopoietic System, pp. 155–182. Berlin, Springer (1982).
Marsh J C: The effects of cancer chemotherapeutic agents on normal haemopoietic precursor cells: a review.Cancer Res 36, 1853 (1976).
Ross D D, Thompson B W, Joneckis C C, Adman S A, Schiffer C A: Metabolism of Ara-C by blast cells from patients with ANLL.Blood 68, 76 (1986).
Fairchild C R, Maybnum J, Kennedy K A: Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment.Biochem Pharmac 35, 3533 (1986).
Goldberg J H, Friedman P A: Antibiotics and nucleic acids.Ann Rev Biochem 60, 775 (1971).
Ando S, Nakamure T, Kagawa D, Ueda T, Nishimura T, Kubo A, Tsutani H, Sasade M, Uchino H: Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells.Cancer Treat Rep 70, 835 (1986).
Deinard A S, Fortuny I E, Theologides A, Anderson G I, Boen J, Kennedy B J: Studies on the neutropenia of cancer chemotherapy.Cancer 33, 1210 (1974).
Greenberg P L, Van Kersen I, Misney S: Cytotoxic effects of cytosin arabinoside and 6-thioguaninein vitro on granulocytic progenitor cells.Cancer Res 36, 4412 (1976).
Buick R N, Messner H A, Till J E, McCulloch E A: cytotoxicity of adriamycin and daunorubicin for normal and leukaemic progenitor cells of man.J nat Cancer Inst 62, 249 (1979).
Valeriote F, Putten L V: Proliferation-dependent cytotoxicity of anticancer agents: a review.Cancer Res 35, 2619 (1975).
Hellman S, Botnick L E: Stem cell depletion: An explanation of the late effects of cytotoxins.Int J Radiat Oncol biol Phys 2, 181 (1977).
Lotem J, Sachs L: Potential prescreening for therapeutic agents that induce differentiation in human myeloid leukaemia cells.Int J Cancer 25, 561 (1980).
Papac R J: Differentiation of human promyelocytic leukaemia cellsin vitro by 6-thioguanine.Cancer Lett 10, 33 (1980).
Schwartz E L, Sartorelli A C: Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukaemia cells by anthracyclines.Cancer Res 42 2651 (1982).
Rowley P T, Ohlsson-Wilhelm B M, Farley B A, LaBella S: Inducers of erythroid differentiation in K562 human leukaemia cells.Exp Haemat 9, 32 (1981).
Griffin J, Munroe D, Major P, Kufe D: Induction of differentiation of human myeloid leukaemia cells by inhibitors of DNA synthesis.Exp Haemat 10, 774 (1982).
Sachs L: Haematopoietic growth and differentiation factors and the reversibility of malignancy: cell differentiation and by-passing of genetic defects in leukaemia.Med Oncol Tumor Pharmacother 3, 165 (1986).
Pierce G B, Speers W D: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation.Cancer Res 48, 1996 (1988).
Gabrilove J L, Welte K, Harris P, Platzer E, Lu L, Levi E, Mertelsmann R, Moore M A S: Pluripoietin-A: a second human hematopoietic colony stimulating factor produced by the human bladder carcinoma cell line 5637.Proc nat Acad Sci 83, 2478 (1986).
Collins S J, Bodner A, Ting R, Gallo R C: Induction of morphological and functional differentiation of human promyelocytic leukaemia cells HL-60 by compounds which induce differentiation of murine leukaemia cells.Int J Cancer 25, 213 (1980).
Brown A E, Armstrong D:Infectious Complications of Neoplastic Disease: Controversies in Management. New York, Yorke Medical (1984).
Cheson B D, Simon R: Low-dose Ara-C in acute nonlymphocytic leukaemia and myelodysplastic syndromes: a review of 20 years’ experience.Sem Oncol 14, 126 (1987).
Hassan H T, Rees J K H: Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human acute myelomonocytic and monoblastic leukaemia cells.Haemat Oncol 6, 39 (1988).
Francis G E, Guimaraes J E T E, Berney J J, Wing M A: Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and AML.Leuk Res 9, 573 (1985).
Nagler A, Kletter Y, Ricklis I, Gazit E, Tatarsky I, Fabian I: Effect of cytosine arabinoside on differentiation of normal human bone marrow cells.Exp Haemat 14, 241 (1986).
Dodion P, Bron D, Mattelaer M A, Delforge A, Rozencweig M, Stryckmans P, Kenis Y: Sensitivity of normal human bone marrow myeloid progenitor cells to Anthracycline, Cisplatin, Anthracene and Flavine acetic acid derivatives, and its relevance for the prediction of human plasma concentrations of anticancer drugs.Eur J Cancer clin Oncol 23, 1902 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hassan, H.T., Rees, J.K.H. Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-d and aclacinomycin a stimulates the differentiation of normal human marrow myeloid progenitor cells. Med. Oncol. & Tumor Pharmacother. 6, 213–217 (1989). https://doi.org/10.1007/BF02985193
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02985193